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Abstract
Purpose: To evaluate in vitro cytotoxicity/biocompatibility as well as in vivo tolerability of the novel polysaccharide
4DryField PH, certified for haemostasis and adhesion prevention.
Methods: In vitro cytotoxicity/viability testing according to ISO EN 10,993 using murine and human tumour cell lines
incubated with 4DryField PH (PlantTec Medical GmbH). Using a rat model the impact of 4DryField PH on animals
viability and in vivo effects were macro- and micropathologically assessed.
Results: In vitro testing revealed no cytotoxic effect of 4DryField PH nor enhancement of viability to tumour cell lines.
In vivo viability of rats was unimpaired by 4DryField PH. Bodyweight loss in animals with abdominal injury plus treatment
with 4DryField PH was in the range of controls and less than in injured rats without treatment. At day 7 after surgery
no formation of adhesions, neither macroscopic nor histological remnants nor signs of foreign body reaction were
present in animals without injury. In animals with peritoneal injury and 4DryField PH application, histopathological
observation revealed minor residuals of polysaccharide in the depth of wound cavity embedded in a thickened subper-
itoneal layer; however, with a suggested intact neoperitoneum. The presence of mononuclear cells surrounding poly-
saccharide particles in varying states of degradation was observable as well.
Conclusion: 4DryField PH is not cytotoxic and does not enhance viability of tumour cell lines. High dose of
4DryField PH of 1.09 g/kg bodyweight is well tolerated and reduces weight loss in animals with peritoneal injury.
The biocompatibility of 4DryField PH can be rated as being excellent.
Keywords
4DryField PH, polysaccharide, haemostatic agent, adhesion prevention agent, biocompatibility, cytotoxicity, rat model
Introduction
If conventional measures for haemostasis like compres-
sion, cautery and suturing are not applicable or success-
ful, other techniques such as the use of topical
haemostats have to be taken into consideration.1
Most of these are cellulose-based or derived from mam-
malian and/or human components. They exert their
eﬀect in various ways like primary improvement of
haemostasis, stimulation of ﬁbrin formation or provid-
ing pro-coagulant substances on vehicles such as colla-
gen.1 The use of modiﬁed starch particles for
haemostasis is a relatively recent addition to the
haemostatic arsenal. Applied as powder to bleeding
areas, polysaccharide particles absorb water from the
wound blood resulting in concentration of plasmatic
ﬁbrinogen and accelerating the natural blood clotting
process.2–4 In a situation of diﬀuse bleeding, a larger
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quantity of haemostatic agent might be of necessity,
raising the question of biocompatibility of those agents.
Adhesions can be a result of previous surgery. They
might lead to considerable patient morbidity and are a
mounting burden for surgeons, patients and the health
care system.5–7 Prophylaxis of adhesions including the
use of biodegradable agents gains more and more
awareness.7,8 Extensive abdominal and pelvic surgery
including operations for symptomatic adhesions can
result in large peritoneal defects necessitating large
quantities of adhesion prevention agents. Again the
question of biocompatibility arises.
The novel agent 4DryField PH (PlantTec Medical
GmbH, Bad Bevensen, Germany) is certiﬁed for
haemostasis and adhesion prevention, both actions
base on its excellent capability to absorb water.
A study investigating the haemostatic eﬀect of
4DryField PH revealed that blood clots formed in
the presence of 4DryField PH have the same physical
properties like genuine clots even if there is 50% hae-
modilution by a relative increases of coagulation fac-
tors by water absorption.3 With respect to adhesion
prevention it was shown that a gel formed from
4DryField PH is highly eﬀective as a barrier against
adhesion formation.9,10
This study investigates the biocompatibility of
4DryField PH. With in vitro testing on murine and
human cells, a potential cytotoxic eﬀect of 4DryField
PH is analysed. For the in vivo testing a previously
described rat model is used.10,11 Biocompatibility is
assessed with viability scoring, course of bodyweight
and macroscopic and histopathological investigations.
Materials and methods
In vitro cytotoxicity tests
To evaluate the impact of 4DryField PH on cell
growth and viability, two assays were performed.
The MTS assay is a standard procedure to estimate
the viability of mammalian cell cultures. In the con-
ducted assay a CellTiter 96 Aqueous One Solution
Cell Proliferation Assay kit (Promega, USA) was
used. For viability testing murine ﬁbrosarcoma L929
cells were cultivated in 96-well plates in Roswell Park
Memorial Institute (RPMI) 1640 cell culture medium
with 10% fetal calf serum. The metabolic rate was stan-
dardised to background signals of culture medium
without cells (blank). As control, negative (aged cell
culture medium), not cytotoxic (reference material in
accordance with ISO 10993-12) and cytotoxic (refer-
ence material in accordance with ISO 10993-12) con-
trols were conducted. The mean viability score of the
negative control was deﬁned as 100% viability. Eight
replicates were performed for each sample. In the assay,
4DryField PH was applied to the culture medium as
an extract prepared as followed:
In accordance with ISO EN 10,993-12-2009, a
material to extraction ratio of 0.2 g/mL was used plus
additional 15mL absorption volume per 1 g
4DryField PH. Therefore, 1 g 4DryField PH per
20mL RPMI 1640 cell culture medium with 10%
fetal calf serum (0.05 g/mL) was used and the solution
was incubated for 24 h at 37C, 5% CO2 and 92%
humidity. After this procedure, the saturated
4DryField PH solution was centrifuged and the result-
ing supernatant was termed ‘100% extract’. Dilutions
of the extract were prepared with RPMI medium and
incubated for 24 h at 37C. According to ISO EN
10,993-5, cytotoxicity should be considered where the
viability value falls below 70% of the negative control.
Viabilty results obtained with 4DryField PH referred
to negative controls.
To evaluate the impact of 4DryField PH powder
on the viability of human cells using a standard Cell
Titer 96 Non-Radioactive Cell Proliferation Assay
(Promega, Germany), 4DryField PH was applied as
a powder directly on the surface of A549 cells. A stan-
dardised MTT assay was performed. Human A549 cells
were grown in 24-well or 96-well plates in concentra-
tions of 40,000–15,000 cells per plate in RPMI cell
culture medium. Before 4DryField PH application,
a 24–72 h cell adhesion and recovery phase was carried
out, followed by the evaluation of cell viability after
24 h of 4DryField PH exposition. 4DryField PH
was added as a powder directly to adherent A549
cells in concentrations varying from 0.001–15mg/mL
4DryField PH per total culture medium. Each concen-
tration was tested as triplicate. Viability scores refer to
controls without 4DryField PH powder in culture
medium as 100% viability.
In vivo testing for 4DryField PH tolerability
Preoperative preparation. To assess the tolerability of
4DryField PH in vivo, male Lewis rats were used in
this study. All protocols were conducted in accordance
with animal protection laws. Animal experiments were
performed at Zentrales Tierlabor of Hannover Medical
School (MHH, Hanover, Germany), providing the
knowledge (housing, caretaking, etc.) to assure life
quality of laboratory animals. The Lower Saxony
State Oﬃce for Consumer Protection and Food
Safety (LAVES) approved this study. Rats had con-
tinuous access to fresh water and were fed ad libitum.
Animals’ welfare was assessed by monitoring of body-
weight and behavioural changes with the use of a
standard observation chart (body condition scoring,
GV-SOLAS, Charite´ -Universita¨tsmedizin Berlin)
(Table 1).
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Surgical procedure. General anaesthesia was achieved by
intraperitoneal injection of 80mg/kg bodyweight
Ketamine and 5mg/kg Xylazine. The required level of
narcosis for surgery was reached if ﬂexor reﬂexes failed
to appear. The abdomen was shaved and disinfected.
A 3 cm median laparotomy was performed to gain
access to the abdominal cavity. After treatment accord-
ing to grouping (see Test groups), the abdomen was
closed using a two-layer closure technique and a
consecutive suture. All animals were sacriﬁced at trial
day 7 by carbon dioxide narcosis followed by cervical
dislocation. The peritoneal cavity was re-entered via an
incision remote to the former laparotomy scar. The
abdominal cavity was thoroughly explored and healing
of provoked abdominal injuries was evaluated. Sample
material of the cecum and abdominal wall for histo-
logical assessment was taken according to a standard
protocol.
Postoperative management. After surgery, animals were
monitored until complete awakening and kept warm
with an infrared lamp. Concerning expectable post-
operative pain in the postoperative period, animals
received Novalminsulfon (non-recurring subcutane-
ously after surgery with 200mg/kg bodyweight and
continuously by mixing 1 g in 500mL drinking water).
Test groups. Prior to the surgical intervention, rats were
separated into four groups: 10 animals received only
laparotomy and closing of the abdomen (group 1).
These animals were used as controls to assess the
impact of surgical procedure on animal behaviour
and weight course. Additional eight rats received
300mg of 4DryField PH in the lower right abdomen
in addition to the laparotomy (group 2). Group 2 was
used to evaluate the impact and safety of 4DryField
PH given into the unimpaired abdomen. In addition,
the eﬀect of 4DryField PH on animals with a severe
abdominal lesion and its subsequent healing process
was analysed. In both lesion groups (groups 3 and 4),
abrasion of the cecum and a wound in the opposite
abdominal wall were created to simulate bleeding and
to form trauma areas. Therefore, the cecum was treated
with a gauze swab to remove visceral peritoneum and
provoke capillary bleeding in an area of 1 2 cm.
Additionally, an about 1 2 cm sized patch of par-
ietal peritoneum with its underlying inner muscular
layer was resected oﬀ the right abdominal wall lat-
eral to the midline laparotomy. Of those treated,
15 rats served as control to evaluate regular wound
healing and bodyweight courses (group 3). Another
14 rats were treated in the same manner followed by
application of 300mg of 4DryField PH (group 4).
4DryField PH powder was given in the area of
injury (group 4) or rather in the right lower abdom-
inal quadrant (group 2). All animals received 1.5ml
saline solution 0.9% in the peritoneal cavity at the
end of surgery. If 4DryField PH was applied, this
procedure was used to transform the starch powder
into a gel.
Evaluation parameters. Animals’ constitution was sub-
jected to daily routine observations and was scored
according to GV-SOLAS (Table 1). Bodyweight was
determined at trial day 0 (before surgical procedure)
and at least on trial day 7. Upon autopsy at postopera-
tive day 7, the abdominal cavity in general, as well as
the areas of cecum and the abdominal sidewall in par-
ticular, were macroscopically evaluated and searched
for polysaccharide remnants.
Histology. Specimen for histological examinations were
collected from all animals to evaluate whether
4DryField PH had an impact on unimpaired tissue
and wound healing and to investigate 4DryField PH
degradation characteristics. Samples were excised en
bloc and ﬁxed in 4% formaldehyde solution. After pro-
cessing, specimens were embedded in paraﬃn blocks.
Serial sections were stained with haematoxylin and
eosin or Alcian blue and PAS stain kit (Sigma-
Aldrich, St. Louis, USA), respectively, and visualised
by light microscopy. 4DryField PH polysaccharide
remnants were detected by PAS staining (blue/purple
colour of polysaccharides). Both, the macroscopic and
the histopathological observers were blinded to the
study.
Table 1. Viability scheme covering days 1–7 after surgery according to GV-SOLAS.
Grade Quality Criteria
1 Agile, active Typical fast movement, curiosity, feed and water intake
2 Active Typical movement, rarely persistent, normal feed and water intake
3 Limited active Reaction to environmental stimulus, frequent persistence, limited feed and water intake
(loss of weight< 20%)
4 Retarded Sleepiness, retarded movement and reaction, excessive limited feed and water intake
(loss of eight> 20%)
5 Lethargical No activity, no reaction, no feed and water intake
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Statistical analysis. Statistical analyses of bodyweight
courses were performed using GraphPad PRISM soft-
ware for a two-way multi-comparison ANOVA cor-
rected for multiple comparison with Turkeys post-hoc
test. Signiﬁcance levels were set as p< 0.05.
Results
In vitro cytotoxicity assays
Two diﬀerent in vitro cytotoxicity assays were con-
ducted to reveal 4DryField PH impact on cell viabil-
ity. On L929 cells the 100% 4DryField PH extract
resulted in a mean viability score of 86.5 4.8% in
the used MTS assay. Extract dilutions of 50%, 25%
and 12.5% revealed viability scores of 103.7 5.4%,
100 6.9% and 99.1 6.7%, respectively. These results
indicated no cytotoxicity of 4DryField PH extract
(Table 2).
Varying amounts of 4DryField PH powder were
applied directly on the surface of adherent A549 cells
to analyse cell viability of human cells in direct contact
with 4DryField PH powder. Figure 1 shows testing of
diﬀerent amounts of 4DryField PH powder in culture
medium and its subsequent inﬂuence on cell viability
referring to a control without 4DryField PH.
4DryField PH amounts ranging from 0.001 to
15mg/mL 4DryField PH were applied, resulting in
viability scores between 111% and 72% with a mean
cell viability of 87.8 15.5%.
Thus, in vitro testing of 4DryField PH when admin-
istered to tumour cell lines in an extract form or a
powder showed neither cytotoxic nor beneﬁcial eﬀects
on tumour cell viability.
In vivo 4DryField PH tolerability
On the ﬁrst day after surgery, all rats were graded with
a GV-SOLAS viability score of 1 and/or 2 (Table 1).
Throughout the remaining study all animals were
graded with a viability score of 1 (Table 3), meaning
that neither the surgical procedure nor the 4DryField
PH application did sustainably inﬂuence animals’
viability.
Surgery was performed without complications, and
due to a plain postoperative course no animal had to be
sacriﬁced or died during the course of investigations.
Table 4 summarises the animal grouping and preopera-
tive bodyweight. All rats of groups 2 and 4 received the
same amount of 4DryField PH (300mg). Preoperative
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Figure 1. Influence of varying amounts of 4DryField PH powder on cell viability of human tumour cell line A549 in a standardised
MTT assay after incubation for 24 h.
Table 2. Median, mean and standard deviation of murine
tumour cell line L929 viability after incubation for 24 h with
4DryField PH-RPMI extract in different concentrations.
Concentration
of extract (%) Median
Mean value standard
deviation Result
100 86.6 86.5 4.8 Not cytotoxic
50 104.1 103.7 5.4 Not cytotoxic
25 99.5 100.0 6.9 Not cytotoxic
12.5 99.2 99.1 6.7 Not cytotoxic
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bodyweight of these animals was in a range of
276–431 g. Hence, the amount of 4DryField PH
given varied from 0.7 to 1.09 g 4DryField PH/kg
bodyweight.
The average bodyweight loss of all rats was
4.6 3.8% one week after surgery (Table 5). Weight
loss was most pronounced in animals with cecal abra-
sion and abdominal wall defect but without 4DryField
PH treatment (group 3, mean weight loss 23 g; 7.2%)
(Figure 2). In contrast, in group 1 mean weight loss was
10 g (2.9%), 14 g (3.4%) in group 2 and 14 g (3.7%) in
group 4. Interestingly, the animals with surgical lesions
and 4DryField PH treatment (group 4) revealed a
course of bodyweight similar to groups 1 and 2 without
lesions (Figure 2). Statistical analyses showed a signiﬁ-
cant diﬀerence between animals of group 1 and group 3
with increased weight loss in group 3 (p¼ 0.04).
Additionally, group 3 showed a signiﬁcantly increased
weight loss compared to animals of group 4 (p¼ 0.04).
By deﬁning bodyweight depending cohorts (Table 6)
mean values of 0.72–1.06 g 4DryField PH / kg body-
weight were applied. The amount of 4DryField PH
administered seemed to have no adverse eﬀect on the
course of viability and bodyweight, even when applied
in a concentration of 1.09 g/kg. Furthermore,
4DryField PH exhibited a beneﬁcial eﬀect on course
of bodyweight in animals with severe surgical injury
(group 4).
Macroscopic inspection of the abdominal cavity of
animals with sole laparotomy (group 1) appeared
inconspicuous. In particular, 4DryField PH-treated
animals (group 2) showed no distinctive features, e.g.
polysaccharide remnants, signs of dehydration or for-
eign body reactions. Rats with cecal abrasion and an
abdominal wall defect (group 3) showed massive adhe-
sions as a result of injured peritoneal tissue. In contrast,
animals with additional 4DryField PH treatment of
group 4 had a normal abdominal cavity and apparently
no adhesions, revealing an anti-adhesive eﬀect of
4DryField PH in injured peritoneal areas. Here the
zones of surgical injury had regained a shiny surface,
appearing like healthy mesothelium. In the area of the
abdominal wall defect, some zones appeared whitish (so
called Winny eﬀect, named after its discoverer).
Histopathological assessment of 4DryField PH
impact on tissue structure is visualised in a representa-
tive animal of group 2 in Figure 3(c) and (d). The overall
impression of cecum and abdominal wall tissue struc-
ture and layering appeared normal as compared to ani-
mals of group 1 (Figure 3(a) and (b)). Besides few
accumulations of mononuclear cells in some regions of
submesothelial layer of the abdominal wall the admin-
istration of 4DryField PH in the healthy abdominal
cavity revealed no abnormalities (Figure 3(d)).
In rats of group 3, the abdominal and cecal wall
tissue layers were agglutinated with ﬁbrous tissue sec-
tions and, thus, did not show normal tissue layering or
Table 5. Comparison of pre- and postoperative bodyweight.
Group
Mean bodyweight (g)
(%)
Day 0 Day 7  Weight loss
(1) Control 343 11 333 11 10 7 2.9 2.1
(2) 4DryField PH 409 13 395 17 14 6 3.4 1.4
(3) Control lesion 321 29 297 30 23 17 7.2 5.6
(4) 4DryField PH lesion 358 59 344 54 14 7 3.7 1.6
All rats 351 47 335 48 16 12 4.6 3.8
Table 4. Preoperative bodyweight data of complete cohort of
rats.
Group Weight (g)
Mean
weight (g) 4DF / BWa
(1) Control 327–361 343 11
(2) 4DryField PH 393–431 409 13 0.73 0.02
(3) Control lesion 270–358 321 29
(4) 4DryField PH lesion 276–423 358 59 0.86 0.15
aMean amount of 4DryField PH (4DF) in gram per kilogram bodyweight
(BW).
Table 3. Postoperative viability scoring of animals.
Group
Mean viability grade
Day 1 Day 7 n
(1) Control 1.1 1.0 10
(2) 4DryField PH 1.1 1.0 8
(3) Control lesion 1.0 1.0 15
(4) 4DryField PH lesion 1.2 1.0 14
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functionality (Figure 3(e) and (f)). 4DryField PH-trea-
ted animals of group 4 revealed a normal tissue layering
(despite of the surgical muscular defect) with separated
abdominal wall and intestine. The former lesion
areas showed a thickening of submesothelial layers
(Figure 3(g) and (h)) as an indicator of active healing
processes. Interestingly, the visceral and parietal peri-
toneum seemed to be reconstituted.
In higher magniﬁcation of healed abdominal wall
lesion areas of group 4, a few isolated polysaccharide
particles could be found in varying levels of degrad-
ation (Figure 4). Figure 4(a) and (b) shows a single
remnant particle, surrounded and invaded by mono-
nuclear cells. After complete absorption of
4DryField PH particles, normal granulating tissue
was seen (Figure 4(c)).
Discussion
Several topical haemostatic agents are currently avail-
able exerting their eﬀect in improving primary haemo-
stasis, stimulating ﬁbrin formation or inhibiting
ﬁbrinolysis.1 Oxidised cellulose or oxidised regenerated
cellulose have been used as haemostats for decades and
are still substantially present on the market.1 As plant-
based agents, they are quite well biocompatible baring
a low risk of allergic reactions or transferal of diseases
caused by foreign proteins and/or blood born
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Figure 2. Relative bodyweight loss and standard deviation of animals with sole laparotomy without (group 1, control) and with
4DryField PH treatment (group 2, 4DryField PH) and weight loss of animals with cecal abrasion and abdominal wall defect (group 3,
control lesion) and with 4DryField PH treatment (group 4, 4DryField PH lesion).
Table 6. Influence of 300 mg 4DryField PH given intraperitoneally on animal viability and weight loss in different
weight cohorts.
Weight cohorts n Mean weight (g) d0 Weight loss (%) d0–d7 4DF / BWa
250–300 4 284.5 9.5 2.9 1.8 1.06 0.04
301–350 3 330.6 13.7 2.8 0.5 0.91 0.04
351–400 4 392.8 6 4 1.7 0.76 0.01
401–450 11 415.8 7.4 3.9 1.5 0.72 0.02
aMean amount of 4DryField PH (4DF) in gram per kilogram bodyweight (BW).
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pathogens. However, they have a degradation time of
about 3–4 weeks.1 If left in the body in signiﬁcant
amounts, they can be the focus of severe adverse
events including adhesion formation.1,12–16 Their
appearance as granulomata leads to the suggestion
that degradation time might even be longer than
weeks.17
Since 1970, mammalian derived products mostly
based on bovine, porcine, or other domestic animal
albumin, collagen or gelatin have been used.1,18,19
These agents are often combined with human agents
like thrombin, ﬁbrinogen or other coagulation factors.
Despite improved technologies of screening, transferal
of diseases can still not be ruled out completely.1
Mammalian-based products can be the basis of
allergy and immunologic reaction20 and transient
granulomatous inﬂammation of variable intensity.17,21
Degradation times of 3–4 weeks and longer for colla-
gen- and gelatin-based haemostats implies the patients’
metabolism being faced with foreign proteins for a sub-
stantial period of time. The property of cellulose- and
mammalian-based agents to induce granuloma forma-
tion has been shown in an experimental comparative
study.17 If haemostats include components like glutar-
aldehyde, degradation time can be massively pro-
longed; in spinal surgery this type of haemostat has
been reported to persist for 2 years.22
Current polysaccharide-based haemostatic agents
act by their capability to absorb water leading to a
relative enrichment of coagulation factors. They have
a short retention time in the body1,17 and, thus, exhibit
a low risk to cause a granulomatous reaction.17
A non-pharmacological approach to prevent adhe-
sions is the use of temporary or permanent barriers to
separate the injured tissue from the surrounding organs
throughout the critical time for adhesion formation
during peritoneal healing.5 Since post-surgical regener-
ation of the peritoneum occurs within days,23 a timely
degradation or excretion of devices is desirable to
decrease the risk of an immunological response or for-
eign body reaction.
4DryField PH is a new device being certiﬁed for
both, haemostasis and adhesion prevention.3,9,10 In
case of diﬀuse bleeding or extensive peritoneal defects,
higher amounts of 4DryField PH (exceeding one sur-
gical unit at 5 g powder) might be indicated and the
question of biocompatibility arises.
Cytotoxicity tests of 4DryField PH indicate that
even in the pure extract there is only a slight decrease
of cell viability far from the level of cytotoxicity
(deﬁned as 70% baseline level) according to the
European and US American regulatory administra-
tions. On the other hand and importantly, viability
was not elevated in direct contact and/or extract
Figure 3. Representative Alcian blue stained histologies of cecal and abdominal wall biopsies seven days after 4DryField PH
application in rat abdomen of a representative animal of group 1 (a, b), group 2 (c, d), group 3 (e, f) or group 4 (g, h), respectively.
Pictures (a) and (b) demonstrate normal abdominal wall (A: peritoneum, B: intact muscle layers) and cecal anatomy (C: cecal mucosa).
(c and d) Abdominal wall and cecum after laparotomy and application of 4DryField PH showed normal peritoneum A, muscle
layers B and cecal mucosa C. After application of 4DryField PH abdominal wall and cecum showed an accumulation of mononuclear
cells in the subperitoneal space (arrow), otherwise no pathological features were seen. (e, f) demonstrate a high level adhesion after
creation of an abdominal wall defect (A: mononuclear cells as a sign of inlammation due to healing processes, B: defect in abdominal
wall muscle layers, C: cecal mucosa). (g) Abdominal wall after creating an abdominal wall defect (A defect in muscle layer) and
treatment with 4DryField PH seemed to have an intact neoperitoneum (arrow) with slightly enlarged subperitoneal granulating
tissue. (h) Cecal wall after peritoneal abrasion and treatment with 4DryField PH showed normal cecal mucosa and submucosa C.
The intact neoperitoneum (arrow) had an enlarged subperitoneal fibrous tissue with infiltrating mononuclear cell B.
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dilutions which indicates that tumour derived cell lines
from sarcoma and adenocarcinoma do not proﬁt from
the presence of 4DryField PH. By this 4DryField PH
as powder or gel can be considered in tumour surgery.
Application of 4DryField PH to peritoneal cavity
of rats revealed that the polysaccharide powder did not
induce adverse events, including adhesion formation.
Since no remnants of 4DryField PH could be found
micro- and macroscopically in rats with unimpaired
abdomen, it can be assumed that 4DryField PH gel
disperses on the intact peritoneum; some accumulation
of mononuclear cells subperitoneally indicate that deg-
radation processes might occur there.
Interestingly, animals with abdominal injury by
cecal abrasion combined with a multi-layer abdominal
wall defect and 4DryField PH treatment had a course
of bodyweight comparable to animals with only lapar-
otomy. In contrast, rats with abdominal lesion and
without 4DryField PH treatment revealed a signiﬁ-
cant increased loss of bodyweight, suggesting that
4DryField PH gel given on the injured area might
enhance recovery.
The few 4DryField PH remnants in the area of the
former peritoneal wall defect are the result of a com-
bined eﬀect: 4DryField PH was given there into a deep
wound and trapped additionally by the suture ﬁxed
cecum, resulting in a local enrichment. Overall, the
amount of 4DryField PH found 7 days after surgery
can be judged minor with only few single particles left
surrounded by mononuclear cells. This indicates that
4DryField PH is degraded within days even if large
quantities are locally present. Overall, the data show
that 4DryField PH in amounts of 0.7–1.09 g/kg body-
weight is well tolerated and contributes to favourable
peritoneal healing.
Conclusion
In vitro cytotoxicity testing indicates that 4DryField
PH is not cytotoxic and that on the other hand human
Figure 4. Histology of mesothelial site of abdominal wall at day 7 after creation of a multilayer abdominal wall defect and 4DryField
PH application in a representative animal of group 4 (Alcian blue and PAS staining). The peritoneal wall was already healed with a
continuous neoperitoneum. (a) Overview with A skeletal muscle of abdominal wall, B inner surface of the abdominal wall with intact
neoperitoneum and an enlarged submesothelial layer; C, D and E show different stages of degradation of polysaccharide particles.
(b) Higher magnification of residual polysaccharide particle C, which is surrounded by mononuclear cells. (c) Higher magnification of
resolving groups of mononuclear cells after degradation of polysaccharide particles E.
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and murine tumour cell lines do not proﬁt from the
presence of 4DryField PH. The in vivo studies in
rats with unimpaired abdomen show that doses of up
to 1.09 g/kg bodyweight of 4DryField PH are well
tolerated and are mainly degraded within days.
4DryField PH has no negative impact on animals’
general wellbeing nor on normal peritoneal tissue.
Animals with abdominal injury do gain a beneﬁt from
the application of 4DryField PH by showing reduced
adhesion formation and a favourable course of body-
weight. The biocompatibility of 4DryField PH can be
rated excellent.
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